Details for Patent: 7,612,114
✉ Email this page to a colleague
Which drugs does patent 7,612,114 protect, and when does it expire?
Patent 7,612,114 protects ORSERDU and is included in one NDA.
This patent has six patent family members in five countries.
Summary for Patent: 7,612,114
| Title: | Selective estrogen receptor modulator |
| Abstract: | The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof. |
| Inventor(s): | Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe |
| Assignee: | Eisai R&D Management Co Ltd |
| Application Number: | US11/158,245 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 7,612,114
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 7,612,114 | ⤷ Start Trial | Y | Y | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Start Trial | ||
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | 7,612,114 | ⤷ Start Trial | Y | Y | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,612,114
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2003292625 | ⤷ Start Trial | |||
| Canada | 2512000 | ⤷ Start Trial | |||
| European Patent Office | 1577288 | ⤷ Start Trial | |||
| Japan | 4500689 | ⤷ Start Trial | |||
| Japan | WO2004058682 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
